NCT06212804View on ClinicalTrials.gov

A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

July 19, 2024

Study Completion Date

July 19, 2024

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

VIS954

A humanized IgG4 monoclonal antibody.

OTHER

Placebo

VIS954 Placebo

Trial Locations (1)

92801

Visterra Clinical Site, Anaheim

All Listed Sponsors

lead

Visterra, Inc.

INDUSTRY